This article is more than 5 years old. Information may no longer be current.
Aperion Biologics receives CE mark for ACL reconstruction device
Click Here to Manage Email Alerts
Aperion Biologics Inc. announced that the company has received a CE mark from the European Union and other accepting territories for its Z-Lig ACLR device.
The Z-Lig is designed to provide instant stability and function to the knee while promoting gradual remodeling into human tissue. According to a company press release, the approval is the first time an engineered biologic device for treatment of revision and multiligament ACL reconstruction was granted a CE mark or approved worldwide.
“[The] CE mark approval independently confirm[s] the successful results we saw in our U.S. pilot study, which now has patients with Z-Lig devices 10 years after implantation,” Kevin R. Stone, MD, founder of Aperion Biologics, stated in the release. “The advantage of an off-the-shelf, biologic device is it avoids the weakening of the patient by taking their own tissue.”